Want to see MXCT full AI Analyst Report?
MXCT Stock Chart & Stats
$1.28
$0.03(2.48%)
At close: 4:00 PM EDT
$1.28
$0.03(2.48%)
Day’s Range― - ―
52-Week Range$0.64 - $1.87
Previous Close$1.19
Volume745.95K
Average Volume (3M)430.91K
Market Cap
$120.75M
Enterprise Value$42.95
Total Cash (Recent Filing)$105.69M
Total Debt (Recent Filing)$17.25M
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Nov 11, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding103,206,210
10 Day Avg. Volume346,312
30 Day Avg. Volume430,908
Financial Highlights & Ratios
PEG Ratio-0.48
Price to Book (P/B)0.96
Price to Sales (P/S)4.99
P/FCF Ratio-4.56
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.00Price Target Upside212.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.28
Revenue Forecast (FY)$31.44M
Bulls Say, Bears Say
Bulls Say
Strong Gross-margin EconomicsSustained gross margins near 80% indicate that MaxCyte’s platform and related services have attractive underlying economics. This provides room to fund research, customer support, and commercial expansion, although operating expenses must still be brought into line with revenue.
Strong, Low-leverage Balance SheetA large cash and investment balance with no debt gives MaxCyte financial flexibility to sustain development, support customer adoption, and absorb continued operating losses. Low leverage also reduces refinancing pressure while management works toward improved growth and lower cash burn.
Genentech Partnership And Broad Licensing BaseThe Genentech enterprise agreement expands MaxCyte’s technology exposure across research, clinical development, and cGMP manufacturing. Combined with its existing licensing base, the partnership broadens customer access and creates additional opportunities for platform revenue, milestones, and royalties.
Bears Say
Deep Unprofitability And Negative Cash GenerationMaxCyte has not yet demonstrated a self-funding operating model: substantial operating expenses remain above revenue, while both operating and free cash flow are negative. Continued losses and deteriorating free cash flow can consume the cash reserve and constrain investment if growth does not improve.
Recent Revenue ContractionThe decline in total and core revenue shows that platform demand has not yet translated into consistent growth. Lower sales reduce operating leverage against the existing cost base and make management’s expected return to low single-digit growth in the second half of 2026 important to the outlook.
Gross-margin Pressure From Product MixThe margin decline reflects a greater share of lower-margin instrument revenue and indicates that product mix can materially affect profitability. If mid-70s margins persist while revenue remains soft, less gross profit will be available to offset operating costs and accelerate the path to breakeven.
MaxCyte News
MXCT FAQ
What was MaxCyte, Inc.’s price range in the past 12 months?
MaxCyte, Inc. lowest stock price was $0.64 and its highest was $1.86 in the past 12 months.
What is MaxCyte, Inc.’s market cap?
MaxCyte, Inc.’s market cap is $120.75M.
When is MaxCyte, Inc.’s upcoming earnings report date?
MaxCyte, Inc.’s upcoming earnings report date is Nov 11, 2026 which is in 43 days.
How were MaxCyte, Inc.’s earnings last quarter?
MaxCyte, Inc. released its earnings results on Aug 12, 2026. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.09 by $0.01.
Is MaxCyte, Inc. overvalued?
According to Wall Street analysts MaxCyte, Inc.’s price is currently Undervalued.
Does MaxCyte, Inc. pay dividends?
MaxCyte, Inc. does not currently pay dividends.
What is MaxCyte, Inc.’s EPS estimate?
MaxCyte, Inc.’s EPS estimate is -0.08.
How many shares outstanding does MaxCyte, Inc. have?
MaxCyte, Inc. has 103,206,210 shares outstanding.
What happened to MaxCyte, Inc.’s price movement after its last earnings report?
MaxCyte, Inc. reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.09. Following the earnings report the stock price went up 9.449%.
Which hedge fund is a major shareholder of MaxCyte, Inc.?
Currently, no hedge funds are holding shares in MXCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MaxCyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.00 (212.50% Upside)
$4.00 (212.50% Upside)
Blogger Sentiment
Neutral
MXCT Sentiment 100%
Sector Average 64%
Sector Average 64%
Hedge Fund Trend
Decreased
By 10.9K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-24.18%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-15.96%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
MaxCyte, Inc.
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
MXCT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call portrayed a company that has stabilized near-term revenue, materially reduced operating expenses, and strengthened its strategic positioning through a large enterprise partnership (Genentech), while maintaining a strong balance sheet. These positives were offset by notable year-over-year revenue declines, gross margin pressure due to product mix, and prior partner/program headwinds. Management reiterated guidance and expects a return to growth in H2 2026, with further upside tied to SPL royalties and instrument adoption.View all MXCT earnings summariesMXCT Stock 12 Month Forecast
Average Price Target
$4.00
▲(212.50% Upside)
Technical Analysis
Ownership Overview
2.16% Insiders
10.87% Mutual Funds
29.41% Other Institutional Investors
53.39% Public Companies and
Individual Investors